Journal of Biomedical and Engineering Research
- ISSN: 3065-8780
Sergey Suchkov, Daniel Scherman, Alan Wu, Alena Borisova, Shawn Murphy, David Smith, and Hiroyuki Abe
Personalized and precision medicine (PPM) relies on specific biomarkers to guide clinical decisions, distinguishing between predictive and prognostic biomarkers. Biomarkers are crucial in diagnosis, risk assessment, treatment guidance, and monitoring, with the potential to improve treatment outcomes. Biomarkers are clinically significant to a wide range of medical conditions, including cardiovascular diseases, autoimmune disorders, and neurodegenerative diseases. In cancer research, biomarkers enable risk assessment, diagnosis, prognosis determination, treatment prediction, therapy monitoring, and revolutionizing clinical decision-making. Designing trials for biomarker-guided therapy presents numerous challenges. Despite these, biomarker-guided trials are crucial for advancing personalized medicine and improving patient outcomes. New generation of biomarkers, particularly microRNAs are gathering attention into the realm of personalized and precision medicine due to their diagnostic, prognostic, and predictive biomarker potential. However, new types of biomarkers need to be researched and implemented to harness this potential. Additionally, this article discusses the integration of biomarkers into clinical practice, the direction of potential research, and the transformative impact new types of biomarkers can have on personalized medicine. Ultimately, the article emphasizes the significance of biomarker research in advancing personalized healthcare interventions, improving patient outcomes, and reshaping the healthcare landscape.